Rapid Review Quiz: Insomnia Recent Studies

Stephen Soreff, MD; Helmi L. Lutsep, MD


February 14, 2022

Recent research into the use of daridorexant used change from baseline in wake after sleep onset and latency to persistent sleep (LPS) at months 1 and 3 as its primary endpoints. Secondary endpoints included change in the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) sleepiness domain score and change from baseline in self-reported total sleep time (TST) at months 1 and 3.

A 50-mg dose of daridorexant was linked to a reduction in LPS of 11.7 min at month 3 vs placebo. Compared with placebo, the 25-mg dose was associated with significant reductions in wake after sleep onset at month 1 (11.6 min, P = .0001) and month 3 (10.3 min, P = .0028) compared with placebo. However, the 25-mg dose was not associated with significant differences in LPS at either timepoint. Similarly, the 25-mg dose was linked to improvements in self-reported TST but not to improved IDSIQ sleepiness score. The 10-mg dose was not associated with improvements at any endpoint compared with placebo.

Learn more about daridorexant.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.